Answers are grounded in this paper and cite their sources.
This research uncovers new strategies in MPS 1 CGT therapy, suggesting improved treatment flexibility for patients.
Immusoft’s MPS 1 CGT therapeutic hurdles traditional barriers, eliminating patient preconditioning and enabling redosing
No takes yet. Share an insight, caveat, or question.
Gail Dutton (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: